AMEX · Financial Statements

Calidi Biotherapeutics, Inc. (CLDI) Revenue, Earnings & Financial Statements

$0.56 AMEX: CLDI Market Cap $2.06M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Calidi Biotherapeutics, Inc. most recently reported annual revenue of $0, a net loss of $20.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Calidi Biotherapeutics, Inc.: net profit was positive in 0 of 6 reported years; operating margin moved from -2334.5% to -51395.6%, a shift of -49061.0 percentage points; the most recent year shows a net loss of $20.0M.

Income Statement — 6 Years (USD millions)

Metric202020212022202320242025
Revenue$0$0$0$0$0$0
Operating Expenses$7.0M$11.0M$23.0M$29.0M$22.0M$20.0M
Operating Profit−$7.0M−$10.0M−$23.0M−$29.0M−$22.0M−$20.0M
Operating Margin—-2334.5%-51395.6%———
Other Income−$1.0M$14.0M−$2.0M$0$0$0
Interest$0$1.0M$0$4.0M$1.0M$0
Depreciation$0$0$0$1.0M$2.0M$2.0M
Profit Before Tax−$8.0M$3.0M−$25.0M−$29.0M−$22.0M−$20.0M
Tax rate (%)-0.1%0.3%-0.0%-0.1%-0.1%-0.1%
Net Profit−$8.0M−$11.0M−$25.0M−$29.0M−$22.0M−$20.0M
EPS−$42.24$226.56−$5740.80−$3321.76−$571.20−$95.20

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$10.0M$7.0M$6.0M$5.0M$4.0M$5.0M$6.0M$5.0M$4.0M$4.0M$4.0M$4.0M
Operating Profit−$10.0M−$7.0M−$6.0M−$5.0M−$4.0M−$5.0M−$6.0M−$5.0M−$4.0M−$4.0M−$4.0M−$4.0M
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$8.0M−$7.0M−$6.0M−$5.0M−$4.0M−$5.0M−$6.0M−$5.0M−$4.0M−$4.0M−$4.0M−$4.0M
Tax rate (%)0.0%-0.1%-0.1%0.0%-0.1%-0.1%-0.1%-0.2%0.1%-0.1%-0.1%-0.3%
Net Profit−$8.0M−$7.0M−$6.0M−$5.0M−$4.0M−$5.0M−$6.0M−$5.0M−$4.0M−$4.0M−$4.0M−$4.0M
EPS−$444.80−$390.72−$268.80−$124.80−$37.89−$35.36−$31.84−$35.36−$8.96−$6.88−$2.94−$1.47

Over the 6 years reported for Calidi Biotherapeutics, Inc., borrowings decreased from $12.0M in 2020 to $3.0M in 2025, cash stood at $6.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 1.50 times.

Balance Sheet — 6 Years (USD millions)

Metric202020212022202320242025
Total Assets$2.0M$3.0M$3.0M$10.0M$14.0M$9.0M
Current Assets$1.0M$3.0M$1.0M$4.0M$10.0M$6.0M
Cash$0$2.0M$0$2.0M$10.0M$6.0M
Inventory$0$0$0$0$0$0
Receivables$0$0$0$1.0M$0$0
Fixed Assets$1.0M$1.0M$1.0M$5.0M$3.0M$2.0M
Capital Work in Progress$0$0$0$0$0$0
Investments$0$0$0$0$0$0
Other Assets$0$0$0$0$0$0
Total Liabilities$24.0M$26.0M$53.0M$18.0M$12.0M$5.0M
Current Liabilities$9.0M$26.0M$43.0M$10.0M$9.0M$4.0M
Borrowings$12.0M$5.0M$6.0M$7.0M$7.0M$3.0M
Other Liabilities$13.0M$21.0M$47.0M$11.0M$5.0M$3.0M
Equity$0$0$0$0$0$0
Reserves−$22.0M−$23.0M−$50.0M−$8.0M$2.0M$4.0M

For Calidi Biotherapeutics, Inc., operating cash flow was positive in 0 of 6 reported years; free cash flow in the latest year was negative at $21.0M; free cash flow was positive in 0 of 6 years; financing activities used $1.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 6 Years (USD millions)

Metric202020212022202320242025
Operating Cash Flow−$5.0M−$8.0M−$13.0M−$27.0M−$20.0M−$21.0M
Investing Cash Flow−$1.0M$0−$1.0M−$1.0M$0$0
Financing Cash Flow$0$8.0M$11.0M$1.0M$0−$1.0M
Net Cash Flow−$1.0M$2.0M−$2.0M$2.0M$8.0M−$4.0M
Free Cash Flow−$5.0M−$8.0M−$14.0M−$28.0M−$20.0M−$21.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.04
FCF Yield-694.54%
Quick Ratio1.27
Interest Coverage-112.82
Return 1Y-97.44%
Return 3Y-99.98%
Return 5Y-100.00%

Calidi Biotherapeutics, Inc. (CLDI) financials — frequently asked questions

What is Calidi Biotherapeutics, Inc.'s annual revenue?

Calidi Biotherapeutics, Inc. (CLDI) reported annual revenue of $0 in its most recent fiscal year.

What is Calidi Biotherapeutics, Inc.'s net profit?

Calidi Biotherapeutics, Inc. (CLDI) reported a net loss of $20.0M in its most recent fiscal year.

What is CLDI EV/EBITDA?

Calidi Biotherapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 0.04.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
CLDI Overview CLDI Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.